Genetic markers for diagnosis and pathogenesis of Alzheimer's disease

Kim, Dong Hee; Yeo, Seung Hyeon; Park, Jeong-Min; Choi, Ji Ye; Lee, Tae Hee; Park, Soon Yong; Ock, Mee Sun; Eo, Jungwoo; Kim, Heui‐Soo; Cha, Hee‐Jae

doi:10.1016/j.gene.2014.05.031

Cited by 113 publications

(101 citation statements)

References 118 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Genome-wide association studies revealed that mutations in amyloid precursor protein, presenilin 1, and presenilin 2 are accountable for the rare early-onset autosomal dominant forms of AD, fueling the hypothesis that amyloid is a key causal factor in AD (Armstrong, 2013). The apolipoprotein E gene «4 allele is associated with the more common lateonset and complex forms of AD (reviewed in Kim et al, 2014a). As these studies have progressed, more genes have been identified to be putatively associated with AD, forcing the field to revisit the amyloid hypothesis as the primary the etiology of AD.…”

Section: A Alzheimer's Diseasementioning

confidence: 99%

Therapeutic Potential ofα7 Nicotinic Acetylcholine Receptors

et al. 2015

View full text Add to dashboard Cite

Section: A Alzheimer's Diseasementioning

confidence: 99%

Therapeutic Potential ofα7 Nicotinic Acetylcholine Receptors

et al. 2015

View full text Add to dashboard Cite

“…First, for MRM analysis of the protein data, raw data of protein concentrations were processed using Skyline software and analysed using the MSstats® package (Choi et al, 2014) in R software (Core Team, 2014). This resulted in normalised log transformed relative intensities of protein concentrations, which were exported into SPSS® (SPSS, 2014) to test group comparisons.…”

Section: Discussionmentioning

confidence: 99%

“…This assumption could be validated for dementia (Kim et al, 2014). However, this link between cognitive impairments and Apo levels has not been done for SZ or BD, so far.…”

Section: Introductionmentioning

confidence: 99%

Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder

Knöchel

Kniep

Cooper

et al. 2016

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Please note: Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders. AbstractProteomic analyses facilitate the interpretation of molecular biomarker probes which are very helpful in diagnosing schizophrenia. In the current study, we attempt to test whether potential differences in plasma protein expressions in schizophrenia (SZ) and bipolar disorder (BD) are associated with cognitive deficits and their underlying brain structures.42 plasma proteins of 29 SZ patients, 25 BD patients and 93 non-clinical controls were quantified and analysed using multiple reaction monitoring (MRM) based triple quadrupole mass spectrometry approach. We also computed group comparisons of protein expressions between patients and controls, and between SZ and BD patients, as well. Potential associations of protein levels with cognitive functioning (psychomotor speed, executive functioning, crystallized intelligence) as well as underlying brain volume in the hippocampus were explored, using bivariate correlation analyses.The main finding of this study was that apolipoprotein (ApoC) expression differed between patients and controls; and that these alterations in both disease groups were putatively related to cognitive impairments as well as to hippocampus volumes. However, none of the protein level differences were related to clinical symptom severity.In summary, altered apolipoprotein expression in BD and SZ was linked to cognitive decline and underlying morphological changes in both disorders. Our results suggest that the detection of molecular patterns in association with cognitive performance and its underlying brain morphology is of great importance for understanding of the pathological mechanisms of SZ and BD, as well as for supporting the diagnosis and treatment of both disorders.4

show abstract

“…Circulating miRNAs are currently used as biomarkers not only in cancer but also in neurological diseases. Their intrinsic propensity for high stability in biofluids such as urine, saliva, and serum has made them especially useful for neurological diseases such AD, PD, and Amyotrophic Lateral Sclerosis (ALS) (Cloutier, Marrero, O'Connell, & Morin, 2014;Jin, Wu, Wang, & Li, 2013;Kim et al, 2014).…”

Section: Mirnas Biomarkers For Lndmentioning

confidence: 99%

MicroRNAs

Guibinga¹

2015

Advances in Genetics

View full text Add to dashboard Cite

Genetic markers for diagnosis and pathogenesis of Alzheimer's disease

Cited by 113 publications

References 118 publications

Therapeutic Potential ofα7 Nicotinic Acetylcholine Receptors

Therapeutic Potential ofα7 Nicotinic Acetylcholine Receptors

Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder

MicroRNAs

Contact Info

Product

Resources

About